REPOTRECTINIB for Non-small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 35 adverse event reports in the FDA FAERS database where REPOTRECTINIB was used for Non-small cell lung cancer.
Most Reported Side Effects for REPOTRECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Dizziness | 32 | 17.1% | 1 | 7 |
| Death | 21 | 11.2% | 20 | 1 |
| Nausea | 12 | 6.4% | 0 | 2 |
| Adverse event | 11 | 5.9% | 1 | 6 |
| Neuropathy peripheral | 11 | 5.9% | 0 | 2 |
| Off label use | 10 | 5.4% | 1 | 2 |
| Paraesthesia | 10 | 5.4% | 0 | 0 |
| Balance disorder | 9 | 4.8% | 0 | 1 |
| Pain | 9 | 4.8% | 0 | 1 |
| Hospitalisation | 8 | 4.3% | 0 | 8 |
| Muscular weakness | 8 | 4.3% | 0 | 1 |
| Anaemia | 7 | 3.7% | 0 | 5 |
| Fatigue | 7 | 3.7% | 0 | 0 |
| Gait disturbance | 7 | 3.7% | 0 | 3 |
| Taste disorder | 7 | 3.7% | 0 | 0 |
Other Indications for REPOTRECTINIB
Other Drugs Used for Non-small cell lung cancer
NIVOLUMAB (9,987)
CARBOPLATIN (7,939)
PEMBROLIZUMAB (6,893)
OSIMERTINIB (6,358)
PEMETREXED (5,179)
PACLITAXEL (4,609)
ATEZOLIZUMAB (4,459)
BEVACIZUMAB (4,136)
DURVALUMAB (3,396)
ERLOTINIB (3,359)